Novo Nordisk wins first smart insulin pen approval for diabetes in China | BioWorld
Drugmaker behind Ozempic, Wegovy begins legal proceedings against certain med spas, clinics and compounding pharmacies | CNN
Quality Control Issues at Novo Nordisk's Clayton Plant - Key Site for Weight-Loss, Diabetes Drug Production
Novo Nordisk Foundation invests $136m in new cell therapy facility - Pharmaceutical Technology
Novo Nordisk lifts 2022 outlook after strong quarter, shares jump | Reuters
NovoPen 6 - new reusable insulin pen – Bionic Wookiee
Novo Nordisk - National Association of Diabetes Centres
How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company - YouTube
Signal: Novo partners with Valo Health for up to $2.7bn
Novo Nordisk | The Economist Group - Great Place To Work
Exclusive: Novo Nordisk hires private U.S. firm to handle some Wegovy pen assembly -source | Reuters
Ozempic manufacturer Novo Nordisk's sponsored content to be probed by TGA
Betting on Obesity chapter one: politics, money and a company called Novo Nordisk
Welcome to Novo Nordisk in the U.S. | Novo Nordisk U.S. Website
Novo Nordisk rejects U.S. report on aggressive insulin price hikes | Reuters
reNEW releases its first annual report - reNEW
Pharmacists for the Environment Australia - For our UK colleagues, Novo Nordisk is launching an #insulin pen program! 23 million pre-filled pens are thrown into landfill or incinerated in the UK each
Novo Nordisk to launch two connected insulin pens, taps Flex to manage data | MobiHealthNews
Novo Nordisk is proactively protecting its weight loss drugs from copycats
New leadership for Novo Nordisk | MedNews
Australia And New Zealand Diabetes Devices Companies - Top Company List
Novo Nordisk comments on role of off-label use in Ozempic shortfall
Pharmaceutical News - Australia's untapped potential in clinical trials sector
Australia Diabetes Care Drugs Companies - Top Company List
Once-weekly insulin from Novo Nordisk meets trial endpoints
Ozempic, Weight-Loss Drugs Are Being Investigated For Suicide Risks - Bloomberg
